rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
RAD51 135G>C and TP53 Arg72Pro polymorphisms and susceptibility to breast cancer in Serbian women.
|
24114315 |
2014 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The findings of our case-control study and meta-analysis suggest a significant association between p53 Arg72Pro polymorphism and an increased risk of breast cancer in Indian population.
|
30065615 |
2018 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
19707196 |
2009 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Different genotypes of the Arg72Pro and PIN3 (+16 bp) polymorphisms had no significant impact on survival in breast cancer patients.
|
21365326 |
2012 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings cannot support contribution of rs1042522 polymorphism to breast cancer risk in an Iranian population.
|
31721533 |
2020 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These observations suggested that neither the Ins16bp or Arg72Pro polymorphisms considered separately, nor any related haplotype, were associated with breast cancer risk in BRCA-mutation negative familial cases.
|
18640791 |
2008 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Specifically, two polymorphisms in p53, c.97-147ins16bp and p.Arg72Pro have been analysed as putative breast cancer susceptibility variants, and it has been recently reported that a p53 haplotype combining the absence of the 16-bp insertion and the presence of proline at codon 72 (No Ins-72Pro) was associated with an earlier age at the onset of the first primary tumour in BRCA2 mutation carriers in the Spanish population.
|
18781154 |
2008 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
|
21706156 |
2012 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The TP53 polymorphisms Arg72Pro (Ex4+199 G>C) and Ins16 (IVS3+24 ins16) have been proposed to modify risk of breast cancer associated with germline BRCA1 and BRCA2 mutations.
|
18402691 |
2008 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, the results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53, do not support the hypothesis of the prominent role of common p53 and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer.
|
27569097 |
2016 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic data revealed that the p53 Arg72Pro genotype was found to be greatly associated with breast cancer risk (p<0.001), as well as tumor site (p=0.046).
|
25750340 |
2015 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
An increase in breast cancer-specific mortality was observed for carriers of the germline MDM2 SNP309 rare GG-genotype (range hazard ratios: 2-3) or TP53 R72P heterozygous GC-genotype (range hazard ratios: 1-2) compared to those having the common genotypes within subgroups of tumors displaying a "more aggressive phenotype" gene expression profile.
|
21667122 |
2011 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Arg72Pro and PIN3(16bp duplication) polymorphisms are proposed to have an effective role in structural changes of p53 and have therefore attracted interest as a risk factor for breast cancer in different populations.
|
25854391 |
2015 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results suggest that TP53 c.215G>C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to BC in Moroccan population.
|
29949804 |
2018 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we investigated the effect on breast cancer survival of germline variation in these genes in 925 Finnish breast cancer patients and further analyzed five single nucleotide polymorphisms (SNPs) in PRKAG2 (rs1029946, rs4726050, rs6464153, rs7789699) and PPP2R2B (rs10477313) for 10-year survival in breast cancer patients, interaction with TP53 R72P and MDM2-SNP309, outcome after specific adjuvant therapy and correlation to tumor characteristics in 4,701 invasive cases from four data sets.
|
23034890 |
2013 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we investigated whether MDM2-SNP309 is associated with p53 R72P genetic polymorphism for the risk of breast cancer development in Asian Taiwanese, which has not been well-studied in this regard.
|
21479369 |
2011 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.
|
17909070 |
2007 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequency of the rs1042522 polymorphism of TP53 was significantly higher in all groups of patients with breast cancer compared with the control group.
|
27644661 |
2016 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele distribution of the R72P missense mutation between ethnically diverse Jewish breast cancer cases and average risk controls showed significant differences: among non-Ashkenazi breast cancer cases, 62.5%, 33.3% and 4.2% were homozygous, heterozygous and homozygous for the Arg72, Arg72Pro and the Pro72 polymorphism, respectively, whereas for controls, the distribution was 22.4%, 65.4% and 12.2%, respectively (P=0.00052), and among Ashkenazi breast cancer cases, allele distribution was 68.5%, 29.6% and 1.9%, whereas for controls, the distribution was 50%, 40% and 10%, respectively (P=0.0125).
|
15756275 |
2005 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Taken together, we showed the preferential loss of the rs1042522 C allele, which is protective against BC progression, in breast tumors.
|
21810023 |
2011 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The P53 gene codon 72 Arg/Pro and Her2 gene Ile655Val polymorphisms were not associated with the risk of breast cancer in Turkish women.
|
20380571 |
2010 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies.
|
17387621 |
2007 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the stratified analyses, a significant association between MDM2 SNP309 and breast cancer</span> risk were observed in Asian, but null significant association between TP53 R72P and breast cancer risk were found even in various subgroups.
|
22729912 |
2012 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy.
|
20638924 |
2010 |